Laplace Interventional

Executive Summary

Laplace Interventional is a privately held medical device company based in San Carlos, CA, focused on developing a transcatheter tricuspid valve replacement (TTVR) system for patients with tricuspid regurgitation (TR). The investigational device aims to provide a percutaneous alternative to open-heart surgery, potentially increasing life expectancy and quality of life for the significant underserved TR population. The company's early-stage technology addresses a high unmet need in structural heart disease, where current treatment options are limited. As a preclinical or early clinical-stage company with no disclosed financing or regulatory milestones, Laplace Interventional represents a high-risk, high-reward opportunity in the rapidly evolving TTVR space.

Upcoming Catalysts (preview)

• TBDInitiation of Early Feasibility Study (EFS) enrollment40% success
• TBDPresentation of preclinical or first-in-human data at major cardiology conference50% success
• TBDSeries A or B financing round to support clinical development35% success